Los Angeles - 
(NewMediaWire) - November 16, 2021 - The Schall Law Firm, a national shareholder rights litigation firm,
announces that it is investigating claims on behalf of investors of Novavax,
Inc. (“Novavax” or “the Company”) (NASDAQ: NVAX) for
violations of the securities laws.
The investigation focuses on whether the Company
issued false and/or misleading statements and/or failed to disclose information
pertinent to investors. Novavax is the subject of an article published by Politico
on October 19, 2021, titled: “‘They Rushed the Process’: Vaccine Maker’s
woes hamper global inoculation campaign.” According to the article,
“manufacturing problems are jeopardizing billions of doses earmarked for poor
and middle-income countries.” The article continues, “although Novavax recently
attested to some of its analytics and testing issues … the company’s issues are
more concerning than previously understood, according to two of the people with
direct knowledge of the matter.” Based on this news, shares of Novavax traded
down sharply on October 20, 2021.
If you are a shareholder who
suffered a loss, click here to participate.
We also encourage you to contact
Brian Schall of the Schall Law Firm, 2049
Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also
reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.
The class in this case has not
yet been certified, and until certification occurs, you are not represented by
an attorney. If you choose to take no action, you can remain an absent class
member.
The Schall Law Firm represents
investors around the world and specializes in securities class action lawsuits
and shareholder rights litigation.
This press release may be
considered Attorney Advertising in some jurisdictions under the applicable law
and rules of ethics.
CONTACT:
The Schall
Law Firm
Brian Schall, Esq.
310-301-3335
